Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Drugs Experience for Adolescents With Anorexia

NCT06211517 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2024-05-20
Last updated
2025-09-12

Condition(s) studied

Anorexia NervosaPsychotropic DrugsAdolescent

Investigational drug(s) / intervention(s)

Semi-structured interviews with visual mediationsSemi-structured interviews

Semi-structured interviews with visual mediations: Semi-structured interviews with visual mediations / An hour-long interview

Semi-structured interviews: Semi-structured interviews

Study summary

The purpose of this study is to access to the experiences of adolescents, their parents and healthcare professionals regarding psychotropic drugs in anorexia nervosa.

No preconceived ideas (according to qualitative methods) but a question: what are the participants' perceptions and experiences of psychotropic drugs in anorexia nervosa? In an adolescent medicine department.

Eligibility

Sex
ALL
Min age
12 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: Adolescents : * Aged 12 to 25 years * Suffering from anorexia nervosa (restrictive or mixed) according to DSM-5 (Diagnostic and Statistical Manual) criteria * Received psychotropic drugs (antidepressant treatment and/or APA) during their care, either ongoing or discontinued before this study started Parents of adolescents suffering from anorexia nervosa for whom a psychotropic drug has been prescribed and whose adolescents meet inclusion criteria Healthcare Professionals working with adolescents suffering from eating disorders Exclusion Criteria: Adolescents : * Atypical eating disorder that does not meet the DSM-5 criteria for restrictive or mixed anorexia nervosa * BMI\<15 * Prescription of an antidepressant other than an SSRI (Selective Serotonin Reuptake Inhibitor) * Prescription of an APA for the indication of psychotic symptoms

Primary outcome measure(s)

  • Semi-structured interview — Day of inclusion
    Themes describing adolescent experiences regarding psychotropic drugs in anorexia nervosa - Emergence of themes describing participants' experience from analysis of qualitative interviews (with Interpretative Phenomenology Analysis methodology)

Trial sites (1)

FacilityCityRegionStatus
Maison de Solenn Maison des Adolescents, Cochin Hospital Paris IDF Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06211517 on ClinicalTrials.gov ↗ ← All trials in France